Relburn is committed to developing innovative products to better
the lives of people with inflammatory disorders. The Company’s
lead programs are in NASH (nonalcoholic steatohepatitis) and gout.
Chronic human illness commonly results from dysfunction in multiple physiologic pathways,
and discovery strategies based on concepts of “one-target, one-disease” are proving increas-
ingly unsuccessful. Metabolomics has driven an interest in agents that modulate multiple tar-
gets simultaneously. Targeting cellular function as a system, rather than at a single-target,
may lead to novel classes of effective multi-targeted drugs with fewer side-effects.*
*Paragraph adapted from Schrattenholz A, et al: Methods Mol Biol. 662:29-58, 2010.